Cyclophilin Inhibitor Fast Tracked for Nonalcoholic Steatohepatitis
The Food and Drug Administration (FDA) has granted Fast Track designation to CRV431 for the treatment of nonalcoholic steatohepatitis (NASH). CRV431 works by specifically binding to cyclophilin isomerase enzymes and inhibiting cyclophilin function with high…